SPEAKERS
Anil Sood
AFFILIATION:
The University of Texas, M. D. Anderson Cancer Center, Houston, TX
POSITION TITLE:
Professor, Department of Gynecologic Oncology and Reproductive Medicine
EDUCATION/TRAINING:
1991 M.D., University of North Carolina, Chapel Hill, North Carolina
1986 B.S., Davidson College Davidson, North Carolina
1982 - 84 University of Arkansas, Fayetteville, Arkansas
HONORS:
1992 - 1995 Outstanding Student Teaching Award, University of Florida
1994, 1995 Outstanding performance on CREOG exam award
1995 Outstanding Laparoendoscopic Resident Surgeon, University of Florida
1996 J. G. Moore Award for the best research presentation by a fellow, The Annual Meeting of the Western Association of Gynecologic Oncologists, San Diego, CA.
1997 Best all-around clinical poster. The 28th annual meeting of the Society of Gynecologic Oncologists (SGO).
1998 Young investigator award--Fourth Joint Conference of the American Association for Cancer Research (AACR) and the Japanese Cancer Association meeting.
2002 Invited expert for the Biological Mechanisms of Psychosocial Effects on Disease (BiMPED) conference sponsored by the Basic Biobehavioral Research Branch (BBRB) of the National Cancer Institute, Bethesda, Maryland.
2002 James F. Nolan Award for the best overall research presentation, The Annual Meeting of the Western Association of Gynecologic Oncologists, Newport Beach, CA.
2003 Outstanding educator, The University of Texas M. D. Anderson Cancer Center.
2003 Charles A. Hunter, Jr. Prize Thesis Award, The American Gynecological and Obstetrical Society, Napa, CA.
2004 Invited speaker for the “Exploring the Integration of Psychoneuroimmunology and Tumor Immunology in Cancer Control Research” conference sponsored by the Basic Biobehavioral Research Branch (BBRB) of the National Cancer Institute, Bethesda, Maryland.
2004 James F. Nolan Award for the best overall research presentation, Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Monterey, CA.
2005, 2007 Educator of the month, M. D. Anderson Cancer Center, September, 2005; and July, 2007
2006 - 2009 Faculty Scholar Award, M. D. Anderson Cancer Center.
2008 Elected to Alpha Omega Alpha Honor Medical Society
2007 The Gynecologic Cancer Foundation/Margaret Greenfield/Carmel Cohen, MD “Excellence in Ovarian Cancer Research Award”
2008 Elected Fellow, the American Gynecological and Obstetrical Society
2009 Excellence in Teaching Award, Association of Professors of Gynecology and Obstetrics, M. D. Anderson Cancer Center
2009 Elected Member, the American Society for Clinical Investigation (ASCI)
2010 Elected, Fellow of the Academy of Behavioral Medicine
2011, 2012 America’s Top Doctors for Cancer, Castle Connolly Medical Ltd. (U.S. News & World Report rankings)
2011 GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher
2011 Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Research, M.D. Anderson Cancer Center
2012 Elected Fellow, the American Association for the Advancement of Science (AAAS)
2014 Society for Gynecologic Investigation President’s Achievement Award
2014 Rosalind Franklin Ovarian Cancer Research award (Ovarian Cancer National Alliance)
2015 Making a Difference Award, The Belinda Sue Fund
2015 Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research (SAASCR)
2017 American Cancer Society Research Professor Award
2017 Elected, Association of American Physicians (AAP)
2021 Elected, National Academy of Medicine (NAM)
RESEARCH INTERESTS:
Active Funding:
R35 CA209904 08/02/2017 – 07/31/2024 NCI $600,000 (annual direct costs) Title: Harnessing the power of exosomes for non-coding RNA delivery Role: PI
American Cancer Society Researh Professor Award (RP-16-240-01-TBG) 1/1/17 – 12/31/21 Non-coding RNA cancer therapeutics $400,000 (Annual direct costs Role: PI
The role of macrophages in resistance to anti-VEGF drugs in ovarian cancer (Project 3 - UT MDACC SPORE in Ovarian Cancer) NIH P50 CA217685 $231,000 (annual direct costs) 09/01/17 – 08/31/22 Overall MPIs (Bast and Sood) and PI of Project 3
EphA2 targeting in uterine carcinoma (Project 3 - UT MDACC SPORE in Uterine Cancer) NIH 2 P50 CA098258-06A2 $1,104,876 (direct cost) 09/01/16 – 08/31/21 Role: PI of Project 3
R01 CA177909 12/01/18 – 11/30/23 Platelets promote growth of ovarian cancer $80,000 (annual direct costs) Role: Multiple PI (Afshar-Kharghan and Sood)
Gateway Foundation (Grant No. G-16-100) 07/01/16 – 6/30/19 Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer $800,000 (total award) Role: Co-PI (PI: Westin)
V-Foundation Award Adaptation to anti-angiogenesis therapy $600,000 (total award) Role: Co-PI (PI: Rob Coleman)
Biobehavioral-cytokine interactions in ovarian cancer NIH R01-CA1045 $1,266,373 (direct cost) 6/01/16 - 5/30/21 Role: Co-Investigator, 5% effort (PI - Susan Lutgendorf, Ph.D.)
U01 CA213759 06/01/2017 – 05/31/2022 NIH $373,498 (annual direct costs)Title: Targeted Therapeutics for Ovarian Cancer and Its Microenvironment - treatment and theoretical modeling Role: MPI (Lopez, Sood)
R01 CA227622 $50,125 (Annual direct costs) 08/01/2018 – 07/31/2023 Title: Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer. Role: Co-I (PI: Nagrath)
RP180381 $119,795 (annual direct costs) 03/01/2018 – 02/28/2021 (NCE till 2022 Title: Mass Spectrometry Imaging to Uncover Predictive Metabolic Markers of Ovarian Cancer Surgical Outcome and Treatment Response. Role: Co-I (PI: Eberlin)
R01 CA229907 7/1/2019 – 06/30/2024 NCI $117,740 (Direct costs) Title: Role of RNA activation in Tumor Progression and Metastasis Role: Co-I (PI: Chaluvally-Raghavan)
PUBLICATIONS:
Complete List of Published Work in PubMed
https://pubmed.ncbi.nlm.nih.gov/?term=Anil+Sood